Celcuity Inc. (Nasdaq: CELC) is a clinical-stage biotechnology company focused on the development of targeted therapies for a number of different cancers. Our mission is to extend the lives of cancer patients by developing potential first-in-class therapies and companion diagnostics.
Celcuity’s lead therapeutic candidate, gedatolisib, is a potential first-in-class pan-PI3K and mTOR inhibitor. Celcuity is conducting a Phase 3 registration-enabling clinical trial to evaluate gedatolisib in patients with HR+/HER2- advanced breast cancer. Our CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies.
Data Provided by Quotemedia with delay
There are currently no upcoming events.
Date
Event Title
Thursday, November 14, 2024 at 4:30 p.m. ET
Celcuity Third Quarter 2024 Financial Results Conference Call
Tuesday, November 19, 2024 at 1:15 p.m. ET
Stifel 2024 Healthcare Conference
Thursday, November 21, 2024 at 11:30 a.m. GMT/6:30 a.m. ET
Jefferies London Healthcare Conference